RVNC News and Press, Revance Therapeutics Inc. From 09/19/22

- Glabellar injection of DAXXIFY™ demonstrated a positive effect on eyebrow position - - DAXXIFY™ demonstrated a high response rate and duration of effect ≥24 weeks across all age and race subgroups - Revance Therapeutics, Inc. (Nasdaq: RVNC), a ...

- Oral poster showcasing positive results from Revance’s Phase 2 JUNIPER clinical trial, which demonstrated long-term efficacy and safety with DAXXIFY™ for the treatment of upper limb spasticity (ULS) in adults after stroke or traumatic brain injury - Study r...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced the closing of its previously announced underwritten public offering of...

Revance Therapeutics ( NASDAQ: RVNC ) stock is down 5.9% after-hours after the firm has priced an upsized underwritten public offering of 8M shares of its common stock at a public offering price of $25.00/share for expected gross proceeds to be $200.0M. All of the shar...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced the pricing of an upsized underwritten public offering of 8,000,000 sha...

Biotechnology company Revance Therapeutics ( NASDAQ: RVNC ) is planning an underwritten public offering of $150M shares. The underwriters may also be granted a 30-day option to purchase up to an additional 15% of the shares offered in the offering. The offering is...

The shares of Revance Therapeutics ( NASDAQ: RVNC ) reached the highest level since October intraday Thursday after the biotech announced the FDA approval of its Botox rival Daxxify injection for the improvement of moderate to severe frown lines. The decision on the ne...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Moab Republic / Shutterstock Apple (NASDAQ: AAPL ) stock is a hot topic on Thursday following the tech giant’s latest event showing off new products. Let’s go over all of the biggest anno...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Revance Therapeutics (NASDAQ: RVNC ) stock is jumping 12% and trending on social media today. The company announced this morning that the Food and Drug Administration (FDA) had approved its alternative to Botox. Rev...

Biotechnology company Revance Therapeutics ( NASDAQ: RVNC ) said that the U.S. Food and Drug Administration has approved its DAXXIFY product for injection for the temporary improvement of moderate to severe frown lines in adults. The peptide-formulated neuromodulator ...